CPAD: Reducing Uncertainty Before the First Patient Enrolls References
- Alzheimer’s Association. 2026 Alzheimer’s disease facts and figures. Alzheimer’s & Dementia. 2026;22(4):e71345.
- U.S. Food and Drug Administration. FDA Converts Novel Alzheimer’s Disease Treatment to Traditional Approval. July 6, 2023; and FDA approval of donanemab (Kisunla), July 2, 2024.
- Cummings JL, Goldman DP, Simmons-Stern NR, Ponton E. The costs of developing treatments for Alzheimer’s disease: A retrospective exploration. Alzheimer’s & Dementia. 2022;18(3):469–477.
- Critical Path Institute. Alzheimer’s Consortium Regulatory Successes, Letters of Support and Timeline.
- Critical Path Institute. Critical Path for Alzheimer’s Disease (CPAD) Database.
- Critical Path Institute. Critical Path for Alzheimer’s Disease.
- Romero K, Ito K, Rogers JA, et al. The future is now: Model-based clinical trial design for Alzheimer’s disease. Clinical Pharmacology & Therapeutics. 2015;97(3):210–214.
- Critical Path Institute. C-Path’s CPAD Database Drives Insights into Alzheimer’s Disease. April 25, 2025.
